{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:12Z","timestamp":1793656512469,"version":"4.5.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,15]],"date-time":"2027-01-15T00:00:00Z","timestamp":1799971200000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcyt.2025.102042","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:05:41Z","timestamp":1766592341000},"page":"102042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-4136","authenticated-orcid":false,"given":"Masatoshi","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haryoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-2422","authenticated-orcid":false,"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-3202","authenticated-orcid":false,"given":"Takahide","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-8046","authenticated-orcid":false,"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-1552","authenticated-orcid":false,"given":"Yoshihiro","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-7902","authenticated-orcid":false,"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-9918","authenticated-orcid":false,"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9790-9078","authenticated-orcid":false,"given":"Koichi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-723X","authenticated-orcid":false,"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8263-9902","authenticated-orcid":false,"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4585","authenticated-orcid":false,"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102042_bib0001","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2025.102042_bib0002","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102042_bib0003","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102042_bib0004","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102042_bib0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-T in large B-cell lymphoma - the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.102042_bib0006","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3324\/haematol.2021.280550","article-title":"Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed\/refractory large B-cell lymphoma receiving CAR T cells","volume":"108","author":"Galtier","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.102042_bib0007","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102042_bib0008","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2025.102042_bib0009","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s10147-023-02334-w","article-title":"Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan","volume":"28","author":"Goto","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102042_bib0010","doi-asserted-by":"crossref","first-page":"E907","DOI":"10.1097\/HS9.0000000000000907","article-title":"Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed\/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use","volume":"7","author":"B\u00fccklein","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jcyt.2025.102042_bib0011","first-page":"193","article-title":"Establishment of a Cellular Therapy Registry in Japan, a platform for data sharing for research, industry, and regulatory use","volume":"11","author":"Atsuta","year":"2022","journal-title":"Japn J Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.102042_bib0012","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102042_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102042_bib0014","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood.2022015601","article-title":"Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"140","author":"Cherng","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102042_bib0015","doi-asserted-by":"crossref","first-page":"1155216","DOI":"10.3389\/fimmu.2023.1155216","article-title":"Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed\/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells","volume":"14","author":"Lu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102042_bib0016","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102042_bib0017","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.102042_bib0018","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102042_bib0019","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102042_bib0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102042_bib0021","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.102042_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102042_bib0023","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood.2023023447","article-title":"Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:20:41Z","timestamp":1780816841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925009387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1465324925009387"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102042","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102042"}}